🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Aktis Oncology, Inc.

AKTS Healthcare
$16.36 +$0.05 (0.31%)
Market Cap: $912.85 M
Gurus Holding
3
Popularity Rank
#3027
% of Shares Held
0.36%
Net Activity (Q3 2026)
-$2.11 M

Guru Ownership Trend

Guru Analysis for Aktis Oncology, Inc. (AKTS)

Aktis Oncology, Inc. (AKTS), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q3 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $3.29 M.

Top institutional holders include Steven Cohen and Cliff Asness.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $2.11 M net outflow during the quarter.

Recent activity highlights Steven Cohen who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 68.0%.

Key Holders

Top 5 by Value

Top 5 by Conviction

Recent Activity Breakdown (Q3 2026)

+$2.59 M
Total Buy Value
New Buys 1
Additions 0
-$4.69 M
Total Sell Value
Reductions 2
Sold Out 1

Guru Consensus (Q3 2026)

Based on recent activity
Net Sellers
3
Net Buyers
1

FAQs for Aktis Oncology, Inc. (AKTS)

Major holders include Steven Cohen ($2.59 M), Cliff Asness ($729,696), Renaissance Technologies (RenTech) ($594,594). According to the latest reported data, 3 tracked investment managers collectively hold approximately 200,903 shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $2.11 M, with 1 managers increasing positions and 3 managers reducing holdings.

During the most recent reporting period, 2 managers trimmed their positions, while 1 fully exited AKTS. The total reported sell value was $4.69 M.

Yes, 1 managers opened new positions in AKTS, and 0 increased their existing holdings. The total reported buy value was $2.59 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.00% New Buy 132,886 $2.59 M Q3 2026
0.00% Reduce -22.1% 37,478 $729,696 Q3 2026
0.00% Reduce -68.0% 30,539 $594,594 Q3 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form